By: Sariah Grant, PharmD Candidate c/o 2027             The rise of glucagon-like peptide -1 receptor agonist medications have transformed the course of type 2 diabetes and weight loss therapy. Subcutaneous injectable medications such as  Ozempic, Wegovy, Mounjaro, and Zepbound have become the new standard due to demonstrated efficacy. United States obesity rates have declined from…

By: Zurriya Faran, PharmD Candidate c/o 2031 The visible loss of skin pigmentation often indicates vitiligo, but what happens beneath the surface is far more complex. Traditionally, vitiligo has been explained as an autoimmune disease in which the immune system mistakenly attacks pigment-producing cells. However, newer research suggests that one of the key factors driving…

By: Amanda Kastel, PharmD Candidate c/o 2027 In February 2026, FDA Commissioner Marty Makary stated in a press conference that: “Everything should be over the counter, unless a drug is unsafe, addictive, or requires monitoring.”1 He argued that this approach could reduce medication costs for consumers by bypassing pharmacy benefit managers (PBMs). Additionally, he stated…

By: Aymon Choudhury, PharmD Candidate c/o 2027 APPE questions: How did your APPE rotations shape you, both professionally and personally? APPE rotations helped my transformation from a student into a clinician by shifting my focus from textbook theory to real-world clinical decision-making and interprofessional collaboration. Though I had baseline knowledge from previous classes, I learned…

By: Archana Murugan, PharmD candidate c/o 2029 Overview             Thiamine metabolic dysfunction syndrome (TMDS) refers to a broad term describing a group of rare errors of metabolism in newborns caused by a defect or deficiency in thiamine (vitamin B1). Thiamine (B1) is highly essential for cell function in our bodies, as it is utilized in…

By: Kevin Lee, PharmD Candidate c/o 2028, Angela Yin, PharmD Candidate c/o 2028             The American Thoracic Society, Centers for Disease Control and Prevention (CDC), European Respiratory Society, and the Infectious Diseases Society of America recently published “Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline” in January 2025.…